Tirzepatide (Mounjaro) targets two: GLP-1 and GIP
AY has given paid lectures and sat on advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx
[149] Derived from Table 2 available on [150] History [edit] Between 1849 and 1887, Thomas Addison described a case of pernicious anemia, William Osler and William Gardner first described a case of neuropathy, Hayem described large red cells in the peripheral blood in this condition, which he called "giant blood corpuscles" (now called macrocytes), Paul Ehrlich identified megaloblasts in the bone marrow, and Ludwig Lichtheim described a case of myelopathy
Why they work together: Argireline reduces expression lines (Botox-like effect) Retinol addresses overall skin texture and collagen Different mechanisms = complementary results Application strategy: Morning: Argireline serum (targets expression lines during day) Evening: Retinol Don't mix in same application (pH differences may reduce effectiveness) Syn-Coll (Palmitoyl Tripeptide-5) Compatibility: Excellent
